Serum bile acids in cystic fibrosis patients – glycodeoxycholic acid as a potential marker of liver disease. Issue 1 (January 2022)

• Record Type: Journal Article
• Authors: Drzymała-Czyż, Sławomira; Dziedzic, Krzysztof; Szwengiel, Artur; Krzyżanowska-Jankowska, Patrycja; Nowak, Jan K.; Nowicka, Agata; Aringazina, Raisa; Drzymała, Sylwia; Kashirskaya, Nataliya; Walkowiak, Jarosław
• Is Part Of: Digestive and liver disease. Volume 54:Issue 1(2022)
• Page Start: 111
• Page End: 117
• Publication Date: 2022-01
• Subjects: Cholic acid -- Cystic fibrosis liver disease -- Deoxycholic acid -- Liver cirrhosis; Digestive organs -- Diseases -- Periodicals; Liver -- Diseases -- Periodicals; 616.33005
• DOI: 10.1016/j.dld.2021.06.034
• Languages: English
• ISSNs: 1590-8658

Abstract

Abstract: Background: Cystic fibrosis (CF) and CF-related liver disease can lead to disturbances in bile acid metabolism. Aim: This study determined serum bile acid concentrations in CF to define their usefulness in liver disease assessment. Methods: Primary, secondary and conjugated bile acid levels were measured in three CF groups (25 patients each) exhibiting: liver cirrhosis, other liver disease, no liver disease, and in 25 healthy subjects (HS). Results: Bile acid levels were higher in CF patients than in HS, except for glycodeoxycholic acid (GDCA). However, bile acid concentrations did not differ between patients with cirrhosis and other liver involvement. GDCA and deoxycholic acid (DCA) differentiated CF patients with non-cirrhotic liver disease from those without liver disease (GDCA-AUC: 0.924, 95%CI 0.822–1.000, p <0.001; DCA-AUC: 0.867, 95%CI: 0.731–1.000, p <0.001). Principal component analysis revealed that in CF liver disease was related to GDCA, GGTP activity, severe genotype and pancreatic insufficiency. Conclusions: A CF-specific bile acid profile was defined and shown to relate to liver disease. GDCA differentiates patients with non-cirrhotic liver involvement from those with no detectable liver disease. Hence, GDCA is a candidate for validation as a biomarker of non-cirrhotic progression of liver disease in CF.